Enhancement by PL 14736 of granulation and collagen organization in healing wounds and the potential role of egr-1 expression

Tkalcević VI, Cuzić S, Brajsa K, Mildner B, Bokulić A, Situm K, Perović D, Glojnarić I, Parnham MJ · European Journal of Pharmacology

PL 14736 and PDGF-BB stimulated granulation tissue similarly in both models, but PL 14736 was more active at organising early collagen and induced egr-1 and its repressor nab2 in culture faster than PDGF-BB.

Population

Rat sponge-implant granuloma, full-thickness excisional wounds in db/db diabetic mice, and Caco-2 cells

Intervention

PL 14736 (the pharmaceutical designation of BPC 157)

Comparator

Becaplermin (recombinant PDGF-BB), the approved diabetic-ulcer growth factor

Limitations

Run by PLIVA Research Institute, the company developing the peptide — independent of the Zagreb university group but not disinterested; skin and granuloma endpoints, not musculoskeletal.